Cardiorenal Syndrome Type 4: A Review

被引:56
作者
Clementi, Anna [1 ,2 ]
Virzi, Grazia Maria [2 ,3 ]
Goh, Ching Yan [2 ,4 ]
Cruz, Dinna N. [2 ,3 ]
Granata, Antonio [1 ]
Vescovo, Giorgio [5 ]
Ronco, Claudio [2 ,3 ]
机构
[1] San Giovanni Dio Hosp, Dept Nephrol & Dialysis, Agrigento, Italy
[2] San Bortolo Hosp, IRRI, IT-36100 Vicenza, Italy
[3] San Bortolo Hosp, Dept Nephrol Dialysis & Transplantat, IT-36100 Vicenza, Italy
[4] Selayang Hosp, Dept Nephrol, Selangor, Malaysia
[5] San Bortolo Hosp, Dept Internal Med, Vicenza, Italy
关键词
Cardiorenal syndrome type 4; Chronic kidney disease; Biomarkers; Cardiovascular events; CHRONIC KIDNEY-DISEASE; GELATINASE-ASSOCIATED LIPOCALIN; CORONARY-ARTERY CALCIFICATION; STAGE RENAL-DISEASE; C-REACTIVE-PROTEIN; PERITONEAL-DIALYSIS; CARDIOVASCULAR EVENTS; HEART-FAILURE; CHRONIC-HEMODIALYSIS; NATRIURETIC PEPTIDE;
D O I
10.1159/000350397
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is a bidirectional and complex relationship between the heart and kidneys. This interaction is physical, chemical as well as biological and is also reflected in a strong connection between renal and cardiovascular diseases. Cardiorenal syndrome type 4 (CRS type 4) is characterized by primary chronic kidney disease (CKD) leading to an impairment of cardiac function, with ventricular hypertrophy, diastolic dysfunction, and/or increased risk of adverse cardiovascular events. The incidence of CKD is increasing, and CRS type 4 is becoming a major public health problem associated with a high morbidity and mortality. In this study, we briefly review the epidemiology and pathophysiology of CRS type 4, the role of biomarkers in its early identification, and its management. Copyright (C) 2013 S. Karger AG, Basel
引用
收藏
页码:63 / 70
页数:8
相关论文
共 67 条
  • [1] Dry-Weight: A Concept Revisited in an Effort to Avoid Medication-Directed Approaches for Blood Pressure Control in Hemodialysis Patients
    Agarwal, Rajiv
    Weir, Matthew R.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (07): : 1255 - 1260
  • [2] AMORE A, 1995, J AM SOC NEPHROL, V6, P1278
  • [3] [Anonymous], 2002, KIDNEY INT
  • [4] Elevated Plasma Levels of PAI-1 Predict Cardiovascular Events and Cardiovascular Mortality in Prevalent Peritoneal Dialysis Patients
    Arikan, Hakki
    Koc, Mehmet
    Tuglular, Serhan
    Ozener, Cetin
    Akoglu, Emel
    [J]. RENAL FAILURE, 2009, 31 (06) : 438 - 445
  • [5] Bacteremia Associated with Tunneled Hemodialysis Catheters: Outcome after Attempted Salvage
    Ashby, Damien R.
    Power, Albert
    Singh, Seema
    Choi, Peter
    Taube, David H.
    Duncan, Neill D.
    Cairns, Tom D.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (10): : 1601 - 1605
  • [6] The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels
    Borazan, A
    Ustün, H
    Ustundag, Y
    Aydemir, S
    Bayraktaroglu, T
    Sert, M
    Yilmaz, A
    [J]. MEDIATORS OF INFLAMMATION, 2004, 13 (03) : 201 - 204
  • [7] Canaud Bernard, 2006, Hemodial Int, V10 Suppl 1, pS5, DOI 10.1111/j.1542-4758.2006.01183.x
  • [8] Dialyzer membrane permeability and survival in hemodialysis patients
    Chauveau, P
    Nguyen, H
    Combe, C
    Chêne, G
    Azar, R
    Cano, N
    Canaud, B
    Fouque, D
    Laville, M
    Leverve, X
    Eng, HR
    Aparicio, M
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) : 565 - 571
  • [9] Beta-blockers for coronary heart disease in chronic kidney disease
    Chonchol, Michel
    Benderly, Michal
    Goldbourt, Uri
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (07) : 2274 - 2279
  • [10] Chung SH, 2003, PERITON DIALYSIS INT, V23, P174